UB Paderborn / Katalog / Suche / in CDI

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2023-05, Vol.26 (3), p.425-437

2023

Link zum Volltext

Verfügbarkeit prüfen

The Activity of Crizotinib in Chemo-Refractory MET-Amplified Esophageal and Gastric Adenocarcinomas: Results from the AcSé-Crizotinib Program

Targeted oncology, 2021-05, Vol.16 (3), p.381-388

2021

Link zum Volltext

Verfügbarkeit prüfen

Randomized, double‐blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer

Cancer medicine (Malden, MA), 2018-11, Vol.7 (11), p.5382-5393

2018

Link zum Volltext

Verfügbarkeit prüfen

Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients

British journal of clinical pharmacology, 2010-01, Vol.69 (1), p.58-66

2010

Link zum Volltext

Verfügbarkeit prüfen

Panitumumab Use in Metastatic Colorectal Cancer and Patterns of KRAS Testing: Results from a Europe-Wide Physician Survey and Medical Records Review

PloS one, 2015-10, Vol.10 (10), p.e0140717-e0140717

2015

Link zum Volltext

Verfügbarkeit prüfen

Chemotherapy treatment patterns and neutropenia management in gastric cancer

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2015-04, Vol.18 (2), p.360-367

2015

Link zum Volltext

Verfügbarkeit prüfen

Impact of Primary Tumour Location and Early Tumour Shrinkage on Outcomes in Patients with RAS Wild-Type Metastatic Colorectal Cancer Following First-Line FOLFIRI Plus Panitumumab

Drugs in R&D, 2019-09, Vol.19 (3), p.267-275

2019

Link zum Volltext

Verfügbarkeit prüfen

Panitumumab use in metastatic colorectal cancer and patterns of RAS testing: results from a Europe-wide physician survey and medical records review

BMC cancer, 2017-11, Vol.17 (1), p.798-798, Article 798

2017

Link zum Volltext

Verfügbarkeit prüfen

Reintroduction of Oxaliplatin Is Associated With Improved Survival in Advanced Colorectal Cancer

Journal of clinical oncology, 2007-08, Vol.25 (22), p.3224-3229

2007

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 169

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(166)
Mit Volltextzugriff
(165)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(79)
Life Sciences & Biomedicine
(78)
Humans
(65)
Oncology
(58)
Male
(50)
Middle Aged
(50)
Aged
(49)
Female
(49)
Life Sciences
(36)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(33)
Tumors
(30)
Adult
(28)
Cancer
(28)
Chemotherapy
(28)
Treatment Outcome
(24)
Disease-Free Survival
(23)
Colorectal Cancer
(22)
Fluorouracil - Administration & Dosage
(22)
Metastasis
(21)
Colorectal Neoplasms - Drug Therapy
(20)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

Effect of Interval (7 or 11 weeks) Between Neoadjuvant Radiochemotherapy and Surgery on Complete Pathologic Response in Rectal Cancer: A Multicenter, Randomized, Controlled Trial (GRECCAR-6)

Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial

Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study

Clinical Outcome of the ACCORD 12/0405 PRODIGE 2 Randomized Trial in Rectal Cancer

Comparison of Two Neoadjuvant Chemoradiotherapy Regimens for Locally Advanced Rectal Cancer: Results of the Phase III Trial ACCORD 12/0405-Prodige 2

Patients With Curative Resection of cT3-4 Rectal Cancer After Preoperative Radiotherapy or Radiochemotherapy: Does Anybody Benefit From Adjuvant Fluorouracil-Based Chemotherapy? A Trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group

OPTIMOX1: A Randomized Study of FOLFOX4 or FOLFOX7 With Oxaliplatin in a Stop-and-Go Fashion in Advanced Colorectal Cancer—A GERCOR Study

Can Chemotherapy Be Discontinued in Unresectable Metastatic Colorectal Cancer? The GERCOR OPTIMOX2 Study

Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trial

Enhanced Tumorocidal Effect of Chemotherapy With Preoperative Radiotherapy for Rectal Cancer: Preliminary Results—EORTC 22921

Paraneoplastic Cushing Syndrome in Gastrointestinal Neuroendocrine Tumour

Capecitabine/Mitomycin versus 5-Fluorouracil/Mitomycin in Combination with Simultaneous Integrated Boost Intensity-Modulated Radiation Therapy for Anal Cancer

Circulating Tumor Cells and Circulating Tumor DNA Detection in Potentially Resectable Metastatic Colorectal Cancer: A Prospective Ancillary Study to the Unicancer Prodige-14 Trial

NESC Multicenter Phase II Trial in the Preoperative Treatment of Gastric Adenocarcinoma with Chemotherapy (Docetaxel-Cisplatin-5FU+Lenograstim) Followed by Chemoradiation Based 5FU and Oxaliplatin and Surgery

Optimal treatment strategy after first-line induction therapy in advanced HER2-positive oeso-gastric adenocarcinoma—a retrospective, international, multicentric AGEO study

The Activity of Crizotinib in Chemo-Refractory MET-Amplified Esophageal and Gastric Adenocarcinomas: Results from the AcSé-Crizotinib Program

Clinical Relevance of Viable Circulating Tumor Cells in Patients with Metastatic Colorectal Cancer: The COLOSPOT Prospective Study

Randomized, double‐blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer

Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients

Panitumumab Use in Metastatic Colorectal Cancer and Patterns of KRAS Testing: Results from a Europe-Wide Physician Survey and Medical Records Review

Chemotherapy treatment patterns and neutropenia management in gastric cancer

Impact of Primary Tumour Location and Early Tumour Shrinkage on Outcomes in Patients with RAS Wild-Type Metastatic Colorectal Cancer Following First-Line FOLFIRI Plus Panitumumab

Panitumumab use in metastatic colorectal cancer and patterns of RAS testing: results from a Europe-wide physician survey and medical records review

Reintroduction of Oxaliplatin Is Associated With Improved Survival in Advanced Colorectal Cancer

Suchergebnisse filtern